Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JSPRBullishM&Anews

High materiality9/10

Jasper and Kira merge to expand immunology pipeline with $132M funding

Jul 16, 2026, 5:17 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The combination creates a larger pipeline and clearer runway, plus near-term licensing cash; milestone-driven upside is plausible, though dilution and CVR complexities temper immediate gains.

AI summary

What happened, with direct paths to the underlying reporting

Jasper Therapeutics completes the acquisition of Kira Pharmaceuticals, creating a broader immunology portfolio and securing $132 million in private funding to support milestones through 2028. The Combined Company centers on KP-104, briquilimab, and KP-701, with KP-301 and KP-402 out-licensed to Mirador, accelerating near-term value creation while introducing dilution and execution risks.

Jasper completes all-stock acquisition of Kira; $132M private placement finalized.
KP-301 and KP-402 out-licensed to Mirador for $12M upfront; milestones possible.
Combined company runway funded through 2H2028; multiple clinical milestones planned.
KP-104, briquilimab, KP-701 form expanded immunology pipeline; interim data in 2026-2027.
Post-closing ownership and share count disclosed; significant dilution risk remains.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Jasper and Kira merge to expand immunology pipeline with $132M funding

Jasper to Acquire Kira for $132M Financing; Pipeline Milestones Through 2028

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?